Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018–2022

Abstract

BackgroundIn January 2018, Afghanistan introduced the monovalent oral rotavirus vaccine (Rotarix) nationwide, administered as a 2-dose series at six and ten weeks of age. We describe characteristics of intussusception cases and assess potential intussusception risk associated with Rotarix vaccination in Afghan infants. MethodsMulti-center prospective active hospital-based surveillance for intussusception was conducted from May 2018 to March 2022 in four sentinel sites in Afghanistan. We applied the Brighton Level 1 criteria for intussusception and verified vaccination status by reviewing vaccine cards. We used the self-controlled case series (SCCS) methodology to compare intussusception incidence in the 1 to 21 days after each dose of Rotarix vaccination against non-risk periods. ResultsA total of 468 intussusception cases were identified in infants under 12 months, with 264 cases aged between 28 and 245 days having confirmed vaccination status contributing to the SCCS analysis. Most case-patients (98 %) required surgery for treatment, and over half (59 %) of those who underwent surgery required intestinal resection. Nineteen (7 %) case-patients died. Eighty-six percent of case-patients received the first dose of Rotarix, and 69 % received the second dose before intussusception symptom onset. There was no increased risk of intussusception in the 1–7 days (relative incidence: 0.9, 95 % CI: 0.1, 7.5), 8–21 days (1.3, 95 % CI: 0.4, 4.2), or 1–21 days (1.1, 95 % CI: 0.4, 3.4) following receipt of the first dose or in the 1–7 days (0.2, 95 % CI: 0.3, 1.8), 8–21 days (0.7, 95 % CI: 0.3, 1.5), or 1–21 days (0.6, 95 % CI: 0.3, 1.2) following the second dose. ConclusionRotarix vaccination was not associated with an increased intussusception risk, supporting its continued use in Afghanistan's immunization program. However, there was a high level of death and resection due to intussusception among Afghan infants.